Expression of Sphingosine-1-phosphate (S1P) on the cerebral vasospasm after subarachnoid hemorrhage in rabbits

Tang, Hua; Zhao, Donggang; Chen, Heng; Fang, Ming; Wang, Feifan; Chen, Ying; Tang, Na; Chen, Qianxue

doi:10.1590/s0102-865020150100000001

Cited by 5 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(178) Interestingly, S1P 3 receptors are also reported to mediate the potent constriction of cerebral arteries by S1P,(40) thus providing a novel target of S1P 1 /S1P 3 system in regulating the vascular response after SAH. Tang et al also observed the expression of S1P on the cerebral vasospasm after SAH using a “double hemorrhage” model in rabbit,(179) and they found S1P expression a new marker for the development of cerebral vasospasm. Also, targeting either TNF-α or the S1P signaling pathway after SAH attenuated neuronal apoptosis and improved neurological outcome.…”

Section: Stroke and The Sphingolipid Pathwaymentioning

confidence: 97%

See 1 more Smart Citation

Critical Role of the Sphingolipid Pathway in Stroke: a Review of Current Utility and Potential Therapeutic Targets

Sun

Keep

Hua

et al. 2016

Transl. Stroke Res.

View full text Add to dashboard Cite

Sphingolipids are a series of cell membrane derived lipids which act as signaling molecules and play a critical role in cell death and survival, proliferation, recognition and migration. Sphingosine 1 phosphate acts as a key signaling molecule and regulates lymphocyte trafficking, glial cell activation, vasoconstriction, endothelial barrier function and neuronal death pathways which plays a critical role in numerous neurological conditions. Stroke is a second leading cause of death all over the world and effective therapies are still in great demand, including ischemic stroke and hemorrhagic stroke as well as the post stroke repair. Significantly, sphingolipid activities change after stroke and correlate with stroke outcome, which has promoted efforts to testify whether sphingolipid pathway could be a novel therapeutic target in stroke. Sphingolipid metabolic pathway, the connection between the pathway and stroke, as well as therapeutic interventions to manipulate the pathway to reduce stroke-induced brain injury are discussed in this review.

show abstract

Section: Stroke and The Sphingolipid Pathwaymentioning

confidence: 97%

“…(32, 37, 38, 175–179) S1P was first found to induce vasoconstriction in canine basilar artery and SPC was determined to be a novel mediator of Rho-kinase induced cerebral vasospasm and act as a proinflammatory mediator in cerebral arteries. Further, SPC cerebrospinal fluid (CSF) levels are elevated in SAH patients.…”

Section: Stroke and The Sphingolipid Pathwaymentioning

confidence: 99%

Critical Role of the Sphingolipid Pathway in Stroke: a Review of Current Utility and Potential Therapeutic Targets

Sun

Keep

Hua

et al. 2016

Transl. Stroke Res.

View full text Add to dashboard Cite

show abstract

“…S1P has been shown in vitro to induce vasoconstriction in mouse middle cerebral arteries [ 14 ] and both in vitro and in vivo in canine basilar arteries [ 42 ]. S1P expression has also been demonstrated to be elevated in vasospastic vessels from a rat model of SAH [ 43 ]. In keeping with this, vascular tone was reduced in SphK2 knock-out mouse cerebral vessels with decreased S1P signalling [ 14 ].…”

Section: S1p Signalling After Asahmentioning

confidence: 99%

Sphingosine-1-phosphate Signalling in Aneurysmal Subarachnoid Haemorrhage: Basic Science to Clinical Translation

Gaastra

Zhang

Tapper

et al. 2023

Transl. Stroke Res.

View full text Add to dashboard Cite

Sphingosine-1-phosphate (S1P) is generated intracellularly and, when transported to the extracellular compartment, predominantly signals through S1P receptors. The S1P signalling pathway has been implicated in the pathophysiology of neurological injury following aneurysmal subarachnoid haemorrhage (aSAH). In this review, we bring together all the available data regarding the role of S1P in neurological injury following aSAH. There is agreement in the literature that S1P increases in the cerebrospinal fluid following aSAH and leads to cerebral artery vasospasm. On the other hand, the role of S1P in the parenchyma is less clear cut, with different studies arguing for beneficial and deleterious effects. A parsimonious interpretation of this apparently conflicting data is presented. We discuss the potential of S1P receptor modulators, in clinical use for multiple sclerosis, to be repurposed for aSAH. Finally, we highlight the gaps in our knowledge of S1P signalling in humans, the clinical challenges of targeting the S1P pathway after aSAH and other research priorities.

show abstract

The sphingosine‐1‐phosphate signaling pathway (sphingosine‐1‐phosphate and its receptor, sphingosine kinase) and epilepsy

Wang,

Kong,

Leng

et al. 2024

Epilepsia Open

View full text Add to dashboard Cite

Epilepsy is one of the common chronic neurological diseases, affecting more than 70 million people worldwide. The brains of people with epilepsy exhibit a pathological and persistent propensity for recurrent seizures. Epilepsy often coexists with cardiovascular disease, cognitive dysfunction, depression, etc., which seriously affects the patient's quality of life. Although our understanding of epilepsy has advanced, the pathophysiological mechanisms leading to epileptogenesis, drug resistance, and associated comorbidities remain largely unknown. The use of newer antiepileptic drugs has increased, but this has not improved overall outcomes. We need to deeply study the pathogenesis of epilepsy and find drugs that can not only prevent the epileptogenesis and interfere with the process of epileptogenesis but also treat epilepsy comorbidities. Sphingosine‐1‐phosphate (S1P) is an important lipid molecule. It not only forms the basis of cell membranes but is also an important bioactive mediator. It can not only act as a second messenger in cells to activate downstream signaling pathways but can also exert biological effects by being secreted outside cells and binding to S1P receptors on the cell membrane. Fingolimod (FTY720) is the first S1P receptor modulator developed and approved for the treatment of multiple sclerosis. More and more studies have proven that the S1P signaling pathway is closely related to epilepsy, drug‐resistant epilepsy, epilepsy comorbidities, or other epilepsy‐causing diseases. However, there is much controversy over the role of certain natural molecules in the pathway and receptor modulators (such as FTY720) in epilepsy. Here, we summarize and analyze the role of the S1P signaling pathway in epilepsy, provide a basis for finding potential therapeutic targets and/or epileptogenic biomarkers, analyze the reasons for these controversies, and put forward our opinions.Plain Language SummaryThis article combines the latest research literature at home and abroad to review the sphingosine 1‐phosphate signaling pathway and epileptogenesis, drug‐resistant epilepsy, epilepsy comorbidities, other diseases that can cause epilepsy, as well as the sphingosine‐1‐phosphate signaling pathway regulators and epilepsy, with the expectation of providing a certain theoretical basis for finding potential epilepsy treatment targets and/or epileptogenic biomarkers in the sphingosine‐1‐phosphate signaling pathway.

show abstract

Expression of Sphingosine-1-phosphate (S1P) on the cerebral vasospasm after subarachnoid hemorrhage in rabbits

Cited by 5 publications

References 29 publications

Critical Role of the Sphingolipid Pathway in Stroke: a Review of Current Utility and Potential Therapeutic Targets

Critical Role of the Sphingolipid Pathway in Stroke: a Review of Current Utility and Potential Therapeutic Targets

Sphingosine-1-phosphate Signalling in Aneurysmal Subarachnoid Haemorrhage: Basic Science to Clinical Translation

The sphingosine‐1‐phosphate signaling pathway (sphingosine‐1‐phosphate and its receptor, sphingosine kinase) and epilepsy

Contact Info

Product

Resources

About